Bagnasco Francesca, Di Iorgi Natascia, Roveda Andrea, Gallizia Annalisa, Haupt Riccardo, Maghnie Mohamad
Endocr Pract. 2017 Aug;23(8):929-941. doi: 10.4158/EP171786.OR. Epub 2017 Jun 14.
To evaluate the self-reported prevalence of poor adherence to recombinant human growth hormone (rhGH) therapy in a large, representative sample of Italian children and adolescents and to assess treatment and patient level correlates of poor adherence.
The study was conducted in 46 pediatric centers throughout Italy. A questionnaire was administered to consecutive children/adolescents treated with rhGH or their parents. Eligible patients were represented by subjects aged between 6 and 16 years, of both sexes, on rhGH treatment for at least 6 months. The questionnaire was administered to the person in charge of preparing the injection. Multivariable logistic regression analysis was performed to identify factors independently associated with adherence.
Overall, 1,007 children/adolescents were involved, of whom 24.4% missed 1 or more injections during a typical week and were thus considered as nonadherent. The most frequently reported reasons for missing a dose were being away from home (33.3%), forgetfulness (24.7%), not feeling well (12.9%), and pain (10.3%). Multivariable analysis indicated association between poor adherence and adolescence, low level of parent education, longer duration of treatment, need to convince the child to inject, and low level of awareness of the consequences of not properly following treatment. The likelihood of adherence markedly increased with higher levels of perceived device convenience.
Poor adherence is still a major problem in the treatment of growth disorders. Increasing awareness and reassessment of treatment adherence on an annual basis should be part of clinical practice of pediatric endocrinologists involved with rhGH treatment.
CI = confidence interval GH = growth hormone rhGH = recombinant human growth hormone.
评估在意大利儿童和青少年的一个大型代表性样本中,自我报告的重组人生长激素(rhGH)治疗依从性差的患病率,并评估治疗和患者层面与依从性差相关的因素。
该研究在意大利全国46个儿科中心进行。对连续接受rhGH治疗的儿童/青少年或其父母进行问卷调查。符合条件的患者为年龄在6至16岁之间、男女均有、接受rhGH治疗至少6个月的受试者。问卷由负责准备注射的人员填写。进行多变量逻辑回归分析以确定与依从性独立相关的因素。
总体而言,共纳入1007名儿童/青少年,其中24.4%在典型的一周内漏打1次或更多次注射,因此被视为依从性差。漏打一剂最常报告的原因是离家外出(33.3%)、遗忘(24.7%)、身体不适(12.9%)和疼痛(10.3%)。多变量分析表明,依从性差与青春期、父母教育水平低、治疗持续时间长、需要说服孩子注射以及对未正确遵循治疗后果的认识水平低有关。随着对设备便利性的感知水平提高,依从的可能性显著增加。
依从性差仍是生长障碍治疗中的一个主要问题。提高认识并每年重新评估治疗依从性应成为参与rhGH治疗的儿科内分泌学家临床实践的一部分。
CI = 置信区间;GH = 生长激素;rhGH = 重组人生长激素